Similar articles

• 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.

  Olesen J. Olesen J. Cephalalgia. 2010 Oct;30(10):1157-8. doi: 10.1177/0333102410377671. Epub 2010 Jul 15. Cephalalgia. 2010. PMID: 20855360 No abstract available.
• Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.

  Ferrari MD, Färkkilä M, Reuter U, Pilgrim A, Davis C, Krauss M, Diener HC; European COL-144 Investigators. Ferrari MD, et al. Cephalalgia. 2010 Oct;30(10):1170-8. doi: 10.1177/0333102410375512. Epub 2010 Jun 15. Cephalalgia. 2010. PMID: 20855362 Clinical Trial.
• Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.

  Maggioni F, Pini LA, Zanchin G. Maggioni F, et al. Cephalalgia. 2011 Jul;31(9):1061. doi: 10.1177/0333102411406753. Epub 2011 Apr 21. Cephalalgia. 2011. PMID: 21511951 No abstract available.
• Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.

  Mitsikostas DD, Tfelt-Hansen P. Mitsikostas DD, et al. Cent Nerv Syst Agents Med Chem. 2012 Dec;12(4):241-9. doi: 10.2174/187152412803760627. Cent Nerv Syst Agents Med Chem. 2012. PMID: 22934751 Review.
• 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

  Neeb L, Meents J, Reuter U. Neeb L, et al. Neurotherapeutics. 2010 Apr;7(2):176-82. doi: 10.1016/j.nurt.2010.03.003. Neurotherapeutics. 2010. PMID: 20430316 Free PMC article. Review.